Mochida Pharmaceutical Co., Ltd. (JP:4534)
:4534
Want to see JP:4534 full AI Analyst Report?
Top Page
Mochida Pharmaceutical Co., Ltd.
(4534)
Select Model
Select Model
Rating:66Neutral
Price Target:
¥3,688.00
▲(2.02% Upside)
Action:Downgraded
Date:05/16/26
The score is driven by strong financial resilience from a low-leverage balance sheet and improving earnings, partly offset by materially inconsistent and sometimes negative operating/free cash flow. Technical signals are currently weak (below key moving averages with negative MACD), while valuation is supportive with a moderate P/E and a ~2.34% dividend yield.
Positive Factors
Conservative balance sheet
Very low historical leverage and a large equity base give Mochida financial flexibility to fund R&D, support manufacturing or licensing efforts, and absorb cyclical shocks. This conservatism reduces refinancing risk and preserves optionality for strategic investments over the medium term.
Negative Factors
Volatile cash generation
Large swings and intermittent negative OCF/FCF point to working-capital timing or collection issues that undermine the reliability of reported profits converting to cash. This hampers the company's ability to self-fund capex, dividends, or acquisitions without external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low historical leverage and a large equity base give Mochida financial flexibility to fund R&D, support manufacturing or licensing efforts, and absorb cyclical shocks. This conservatism reduces refinancing risk and preserves optionality for strategic investments over the medium term.
Read all positive factors
Mochida Pharmaceutical Co., Ltd. (4534) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥124.37B
Dividend Yield2.34%
Average Volume (3M)34.37K
Price to Earnings (P/E)19.6
Beta (1Y)0.66
Revenue Growth11.21%
EPS Growth39.02%
CountryJP
Employees1,522
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)169.96
Shares Outstanding36,390,000
10 Day Avg. Volume38,620
30 Day Avg. Volume34,366
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)0.87
Price to Sales (P/S)1.05
P/FCF Ratio-12.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)208.3
Revenue Forecast (FY)¥110.00B
Mochida Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticanc...
How the Company Makes Money
Mochida Pharmaceutical makes money primarily by selling pharmaceutical products, with revenue largely generated from prescription drug sales in the domestic Japanese market. Its core revenue model includes (1) product sales from its own marketed p...
Mochida Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
90
Very Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 106.38B | 116.95B | 105.16B | 102.89B | 103.26B | 110.18B |
| Gross Profit | 54.46B | 56.26B | 53.79B | 52.07B | 55.12B | 59.55B |
| EBITDA | 11.44B | 13.13B | 11.07B | 8.61B | 11.18B | 17.08B |
| Net Income | 6.03B | 7.90B | 5.68B | 4.55B | 6.65B | 10.57B |
Balance Sheet | ||||||
| Total Assets | 161.74B | 182.72B | 163.56B | 162.30B | 161.04B | 165.93B |
| Cash, Cash Equivalents and Short-Term Investments | 54.69B | 31.06B | 51.15B | 46.79B | 60.51B | 61.91B |
| Total Debt | 830.00M | 10.00B | 342.00M | 369.00M | 178.00M | 0.00 |
| Total Liabilities | 30.59B | 42.39B | 32.87B | 34.33B | 34.26B | 37.28B |
| Stockholders Equity | 131.15B | 140.33B | 130.69B | 127.97B | 126.78B | 128.65B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -10.04B | 7.19B | -9.78B | 5.13B | 4.47B |
| Operating Cash Flow | 0.00 | -7.35B | 9.35B | -7.48B | 7.30B | 7.46B |
| Investing Cash Flow | 0.00 | -16.85B | 17.36B | 74.00M | -2.95B | -2.01B |
| Financing Cash Flow | 0.00 | 7.03B | -2.87B | -6.39B | -6.88B | -5.96B |
Mochida Pharmaceutical Co., Ltd. Technical Analysis
Positive
3615.00
Price Trends
3505.47
Positive
3566.46
Positive
3357.32
Positive
Market Momentum
18.91
Negative
63.82
Neutral
90.55
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4534, the sentiment is Positive. The current price of 3615 is above the 20-day moving average (MA) of 3441.50, above the 50-day MA of 3505.47, and above the 200-day MA of 3357.32, indicating a bullish trend. The MACD of 18.91 indicates Negative momentum. The RSI at 63.82 is Neutral, neither overbought nor oversold. The STOCH value of 90.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4534.
Mochida Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥124.37B | 19.64 | 4.81% | 2.34% | 11.21% | 39.02% | |
58 Neutral | ¥169.72B | 17.42 | 6.70% | 2.48% | 10.28% | 20.78% | |
55 Neutral | ¥175.86B | 24.45 | ― | 2.28% | 6.69% | 6.72% | |
54 Neutral | ¥71.27B | -35.21 | ― | 3.36% | -2.94% | -62.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥147.86B | 73.21 | -2.58% | 4.16% | -18.25% | -84.71% | |
48 Neutral | ¥191.44B | -4.17 | 12.02% | 2.14% | 5.44% | -72.35% |
* Healthcare Sector Average
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,655.00
761.60
26.32%
JP:4521
Kaken Pharmaceutical Co
4,105.00
515.61
14.36%
JP:4547
Kissei Pharmaceutical Co
4,155.00
398.04
10.59%
JP:4553
Towa Pharmaceutical Co
3,890.00
889.71
29.65%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,354.00
-54.20
-3.85%
JP:4887
SAWAI GROUP HOLDINGS Co., Ltd.
1,768.00
-89.38
-4.81%
Mochida Pharmaceutical Co., Ltd. Corporate Events
Mochida Pharmaceutical Reshapes Executive Lineup to Sharpen Business Focus
May 15, 2026
Mochida Pharmaceutical announced board-level leadership changes effective June 25, 2026, including revised duties for Representative Directors Junichi Sakaki and Motoi Mitsuishi to streamline oversight across research, biomaterials, pharmaceutical...
Mochida Pharmaceutical Lifts Profits and Raises Dividend Outlook for FY2027
May 15, 2026
Mochida Pharmaceutical reported solid growth for the fiscal year ended March 31, 2026, with net sales rising 11.2% to ¥116.95 billion and profit attributable to owners of parent climbing 39.0% to ¥7.90 billion, reflecting improved margin...
Mochida Pharmaceutical Sets Terms for Secondary Share Offering and Over-Allotment
Apr 6, 2026
Mochida Pharmaceutical has set the terms for a secondary offering of its common stock, establishing an offer price of 3,331 yen per share for shares to be purchased and underwritten by the underwriters, with a total offer value of approximately 3....
Mochida Pharma Clears Audit Review as Profits Rise Ahead of Secondary Share Offering
Mar 30, 2026
Mochida Pharmaceutical said an independent auditor has completed its interim review of the consolidated financial statements for the nine months ended Dec. 31, 2025, clearing the way for a previously approved secondary offering of common shares. T...
Mochida Pharmaceutical Unveils Up to ¥2 Billion Share Buyback Plan
Mar 30, 2026
Mochida Pharmaceutical Co., Ltd. has approved a share repurchase program authorizing the buyback of up to 530,000 shares of its common stock, representing about 1.50% of its outstanding shares excluding treasury stock. The maximum total purchase a...
Mochida Pharmaceutical Plans Secondary Share Offering to Boost Liquidity
Mar 30, 2026
Mochida Pharmaceutical will conduct a secondary offering of 1,153,600 existing common shares through a purchase and underwriting arrangement, with pricing to be set in early April based on market demand and recent Tokyo Stock Exchange trading leve...
Mochida to Acquire Full Rights to URECE Gout Drug from Fuji Yakuhin
Mar 30, 2026
Mochida Pharmaceutical has agreed to take over the manufacturing and marketing approval for URECE Tablets, a dotinurad-based treatment for gout and hyperuricemia, from FUJI YAKUHIN in Japan and to acquire associated assets including patents and tr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.